Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, May 7, 2020.